Globally, lung cancer is the leading cause of cancer death (18.4% of the total cancer deaths) and the most diagnosed cancer (11.6% of the total cases).1 Early detection is one of the most important pillars in the fight against lung cancer, as survival rates correlate with the timing of cancer detection: The earlier the cancer is detected, the higher the chances of survival.2
Our products are designed to support this strategy by providing state-of-the-art solutions to aid in optimizing screening, diagnosis, therapy decision and treatment execution with the goal of increasing the survivorship and quality of life for cancer patients.
Early-stage lung cancer – the road to a cure
Accompany a young female lung cancer patient on her journey through Chang Gung Memorial Hospital, Taiwan, after having received a lung cancer diagnosis. See how early detection and minimally invasive, image-guided thoracoscopic surgery can provide hope.
Siemens Healtineers solutions touch cancer patients along their entire journey:
Lung cancer treatment can be significantly more effective if the disease is detected earlier in stage I or II, before the onset of symptoms when the disease is still localized. This emphasizes the benefit to establish screening programs for earlier detection. Precise lung cancer staging of lymph node involvement and distant metastases determines the prognosis and is the foundation of adequate therapy selection.
Radiotherapy planning demands images that provide reliable information about the tumor and surrounding organs. By enabling Radiation Therapy specialists to look closer at the facts, our tailor-made imaging solutions help achieve prime outcomes for every single patient, and let experts see further than ever before into the future of individualized therapies.
Global Cancer Observatory, WHO, https://gco.iarc.fr/
de Koning et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382(6):503-513
SOMATOM Force is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details
Compared to mCT
Measured value, based on phantom studies performed on a single system. Biograph Vision Quadra has ≤249ps time of flight performance based on acceptance values. Data on file
Biograph Vision Quadra is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.
syngo Carbon consists of several products which are (medical) devices in their own right. Some products are under development and not commercially available. Future availability cannot be ensured.
Casal, R. F., Sarkiss, M., Jones, A. K., Stewart, J., Tam, A., Grosu, H. B., Eapen, G. A. (2018). Cone beam computed tomography-guided thin/ultrathin bronchoscopy for diagnosis of peripheral lung nodules: A prospective pilot study. Journal of Thoracic Disease, 10(12), 6950-6959. doi:10.21037/jtd.2018.11.21; Avasarala, S. K., Machuzak, M. S., & Gildea, T. R. (2020). Multidimensional Precision. Journal of Bronchology & Interventional Pulmonology, 27(2), 153-155. doi:10.1097
Gildea et al.s, J Bronchol Intervent Pulmonols 2020. Mean lesion size in study: 26 mm × 24 mm. The study was performed at a singe center and there can be no guarantee that other customers will achieve the same results.
myNeedle Companion functionality is currently available for ARTIS VE2 as syngo Needle Guidance, laser crosshairs, and applicable scan protocols. myNeedle Companion for ARTIS angiography systems is currently under development and does not yet fulfill all applicable General Safety and Performance Requirements according to the European Medical Device Regulation (EU) 2017/745 (MDR). myNeedle Companion for ARTIS angiography systems is not yet available for sale. Its future availability cannot be guarantee
AI-Pathway Companion Lung Cancer VA10A supports Single primary tumor and Non-small cell Lung cancer cases only. AI-Pathway Companion consists of several health products and medical devices in their own right, and products under development. AI-Pathway Companion is not commercially available in all countries. Their future availability cannot be guaranteed.
Direct i4D is optional and Requires Anzai or Varian RGS
DirectDensity reconstruction is designed for use in Radiation Therapy Planning (RTP) only. DirectDensity reconstruction is not intended to be used for diagnostic imaging
syngo.via can be used as a standalone device or together with a variety of syngo.via-based software options, which are medical devices in their own right. syngo.via is not yet commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further information